TrialBMC cancer2024

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.

Sherko Kuemmel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.